All News

2020

September

Media Release / Sep 21, 2020

Novartis Kisqali® receives the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale

Read More
Media Release / Sep 19, 2020

Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation

Read More
Media Release / Sep 19, 2020

Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma

Read More
Featured News / Sep 17, 2020

Novartis at ESMO

Latest oncology resources and news surrounding Novartis data featured at European Society for Medical Oncology (ESMO)

Read More
Media Release / Sep 16, 2020

Novartis Tafinlar® + Mekinist® demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM

Read More
Patient and healthcare worker in Vietnam
Featured News / Sep 16, 2020

Committed to increasing access

Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.

Read More
Media Release / Sep 16, 2020

Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond

Read More
Alice Shaw
Story / Sep 14, 2020

Bringing science and medicine together to help patients with cancer

Alice Shaw, Global Head of Translational Clinical Oncology at Novartis, applies lessons from running clinical trials to the work of designing them.

Read More
Media Release / Sep 14, 2020

European Medicines Agency (EMA) approves safety label update for Novartis Beovu®

Read More
Media Release / Sep 14, 2020

Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More